SCYX SCYNEXIS INC

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISI’s 3rd Annual HealthCONx Conference taking place on December 2, 2020.

Presentation details:

Piper Sandler 32nd Annual Virtual Healthcare Conference:
Presentation Date:Monday, November 23 to Thursday, December 3, 2020
Presentation Time:8:00 a.m. – 5:00 p.m. ET
Webcast:

 
Evercore ISI 3rd Annual HealthCONx Conference:
Panel Discussion Topic:

No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS

Presentation Date:Wednesday, December 2, 2020
Presentation Time:11:20 a.m. – 12:05 p.m. ET
 

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: .

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit .

CONTACT: 

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (646) 970-4681

Media Relations

Gloria Gasaatura

LifeSci Communications

Tel: (646) 970-4688

 



EN
24/11/2020

Underlying

SCYXSCYNEXIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCYNEXIS INC

 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending D...

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247 JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...

September 30, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Announces Multiple Presentations Highlighting Data from its S...

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending D...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conf...

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025 JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference. Date: Wednesday September 10, 2025Format: In-person presentation and 1x1 meetingsTime: 10:30 a.m.-11:00 a.m. ETLocation: New York, NY If you are intere...

August 25, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Co...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments.  SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to G...

August 13, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch